Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2018—Ortho Clinical Diagnostics and EKF Diagnostics announced an agreement that allows Ortho customers to access EKF’s Beta-Hydroxybutyrate LiquiColor Assay, a CLIA moderate-complexity test for use on Ortho’s Vitros 4600 Chemistry System and Vitros 5600 Integrated System.
February 2018—LGC Maine Standards announced the release of its Validate SP2 linearity and calibration verification kit. The Validate SP2 kit, in a human serum matrix, evaluates albumin, ceruloplasmin, C-reactive protein, haptoglobin, prealbumin, and rheumatoid factor. Each kit offers five distinct concentrations covering the reportable ranges of Roche Cobas analyzers.
February 2018—MedTest announced the commercial availability of four forensic use only urine drug tests for use on its BS-200, BS-480, and BA-800M chemistry analyzers. The four new assays are DRI Fentanyl, Cedia AB-PINACA (spice K2), Cedia UR-144/XLR-11 (spice K2), and DRI Ethyl Glucuronide.
February 2018—Approximately 250 professionals attended an inspector training program organized by National Reference Laboratory, part of Mubadala’s network of health care providers, and the College of American Pathologists. Faculty included members of the CAP leadership as well as worldwide and local experts experienced with the quality accreditation process.
February 2018—Oasis Diagnostics has launched a testing service, through its Oasis Research Laboratory, for salivary hormone biomarker assessment using discreet panels. The service aims to relieve some of the complexity inherent in testing for biomarkers in the research setting.
February 2018—Sekisui Diagnostics and Mesa Biotech announced a strategic alliance to distribute the Mesa Biotech POC molecular system for Flu A/Flu B. Sekisui Diagnostics will assume exclusive distribution of the Mesa Biotech POC system in the United States and Canada, pending FDA clearance.
February 2018—Illumina introduced its NextSeq 550Dx instrument, the company’s second FDA-regulated and CE-IVD-marked next-generation-sequencing system. Illumina also announced that the intended use for the MiSeqDx instrument now includes the use of DNA libraries generated from formalin-fixed, paraffin-embedded tissues.
February 2018—Qiagen and DiaSorin announced a partnership in which Qiagen’s QuantiFeron-TB diagnostic test will be added to the menu of DiaSorin’s Liaison family of analyzers, enabling customers of both companies to process QuantiFeron-TB Gold Plus, a fourth-generation assay for latent tuberculosis detection, on Liaison platforms. QFT-Plus is the first assay from the QuantiFeron portfolio that is planned to be adapted for use on the Liaison systems, with additional assays under consideration.
January 2018—Qiagen and Centogene announced a collaboration and comarketing agreement to provide customers more complete sample-to-insight research and clinical testing solutions in rare genetic diseases. The collaboration includes the integration of Centogene’s CentoMD rare disease variant database into Qiagen’s bioinformatics offering to enhance test interpretation.
January 2018—The Society of Toxicologic Pathology invites CAP members to consider a call for papers and contribute to the publication of a special 2019 issue focusing on medical devices in pathology in support of preclinical studies.
